Isorhamnetin 3-O-galactoside shows antioxidant, anti-inflammatory, neuroprotective,and barrier protective activities, it could be used as a candidate therapeutic for treatment of severe vascular inflammatory diseases.

The anticoagulant activities were investigated by measuring activated partial thromboplastin time (aPTT) and prothrombin time (PT), and the ability to inhibit production of thrombin and activated factor X (FXa) was investigated in human umbilical vein endothelial cells (HUVECs). And, the effects of the compounds on expression of plasminogen activator inhibitor type 1 (PAI-1) and tissue-type plasminogen activator (t-PA) were tested in tumor necrosis factor-(TNF)-α± activated HUVECs. Treatment with IMG and hyperoside resulted in significantly prolonged aPTT and PT and inhibition of the activities of thrombin and FXa, and IMG or hyperoside inhibited production of thrombin and FXa in HUVECs. In accordance with these anticoagulant activities, both agents elicited anticoagulant effects in mouse. In addition, treatment with IMG and hyperoside resulted in inhibition of TNF-α±-induced production of PAI-1, and treatment with IMG resulted in significant reduction of the PAI-1 to t-PA ratio.

6743-92-6

C22H22O12

478.4

异鼠李素-3-O-半乳糖苷;Cacticin

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years